title: Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection.
abstract: BACKGROUND
  The aim of our study was to compare two 1-week, low-dose triple therapies for Helicobacter pylori eradication.
  
  
  METHODS
  One hundred consecutive patients, suffering from dyspeptic symptoms with H. pylori infection, were randomly allocated to 7 days of treatment with omeprazole 20 mg o.m. plus clarithromycin 250 mg b.d. and either tinidazole 500 mg b.d. (group A: n = 50, 19 with peptic ulcer) or amoxycillin 1000 mg b.d. (group B: n = 50, 20 with peptic ulcer). H. pylori-status was evaluated by means of histology, culture and urease test, at entry and 8 weeks after treatment.
  
  
  RESULTS
  Three patients did not complete the treatment. H. pylori eradication was obtained in 35 patients from group A (73%) (95% CI, 55-82%) and in 40 patients from group B (82%) (95% CI, 66-90%). On intention-to-treat analysis, the rates of eradication were similar. Side-effects occurred in seven patients from group A (14.58%) and in four patients from group B (8.33%), but none discontinued therapy because of side-effects.
  
  
  CONCLUSIONS
  Both triple 1-week, low-dose omeprazole therapies gave good eradication rates with infrequent side-effects.
authors.affiliation: Department of Internal Medicine, Catholic University S.C., Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Tursi
authors.forename: G
authors.initials: G
authors.lastname: Cammarota
authors.forename: M
authors.initials: M
authors.lastname: Montalto
authors.forename: A
authors.initials: A
authors.lastname: Papa
authors.forename: G
authors.initials: G
authors.lastname: Veneto
authors.forename: L
authors.initials: L
authors.lastname: Cuoco
authors.forename: F
authors.initials: F
authors.lastname: Trua
authors.forename: G
authors.initials: G
authors.lastname: Branca
authors.forename: G
authors.initials: G
authors.lastname: Fedeli
authors.forename: G
authors.initials: G
authors.lastname: Gasbarrini
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004415:Dyspepsia / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D014011:Tinidazole / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D014011:Tinidazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole